Zevalin: 90yttrium labeled anti-CD20 (ibritumomab tiuxetan), a new treatment for non-Hodgkin's lymphoma. Curr Pharm Biotechnol. 2001 Dec; 2(4):341-9.
Zevalin: 90yttrium labeled anti-CD20 (ibritumomab tiuxetan), a new treatment for non-Hodgkin's lymphoma.
DeBernardo RL, Perkins RB, Littell RD, Krasner CN, Duska LR
Low-molecular-weight heparin (dalteparin) in women with gynecologic malignancy. Obstet Gynecol. 2005 May; 105(5 Pt 1):1006-11.
Low-molecular-weight heparin (dalteparin) in women with gynecologic malignancy.
Penson RT, Campos SM, Seiden MV, Krasner C, Fuller AF, Goodman A, Roche M, Willman A, Muzikansky A, Matulonis UA
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
A phase II study of fixed dose rate gemcitabine in patients with relapsed müllerian tumors. Int J Gynecol Cancer. 2005 Nov-Dec; 15(6):1035-41.
A phase II study of fixed dose rate gemcitabine in patients with relapsed müllerian tumors.
Hesterberg PE, Banerji A, Oren E, Penson RT, Krasner CN, Seiden MV, Wong JT
The Journal of allergy and clinical immunology
Risk stratification for desensitization of patients with carboplatin hypersensitivity: clinical presentation and management. J Allergy Clin Immunol. 2009 Jun; 123(6):1262-7.e1.
Risk stratification for desensitization of patients with carboplatin hypersensitivity: clinical presentation and management.
Campos SM, Berlin ST, Parker LM, Chen WY, Bunnell CA, Atkinson T, Lee J, Matulonis U, Hirsch MS, Harris L, Krasner CN
International journal of clinical oncology
Phase I trial of liposomal doxorubicin and ZD1839 in patients with refractory gynecological malignancies or metastatic breast cancer. Int J Clin Oncol. 2010 Aug; 15(4):390-8.
Phase I trial of liposomal doxorubicin and ZD1839 in patients with refractory gynecological malignancies or metastatic breast cancer.
Esselen KM, Rodriguez N, Growdon W, Krasner C, Horowitz NS, Campos S
Patterns of recurrence in advanced epithelial ovarian, fallopian tube and peritoneal cancers treated with intraperitoneal chemotherapy. Gynecol Oncol. 2012 Oct; 127(1):51-4.
Patterns of recurrence in advanced epithelial ovarian, fallopian tube and peritoneal cancers treated with intraperitoneal chemotherapy.
Matulonis UA, Horowitz NS, Campos SM, Lee H, Lee J, Krasner CN, Berlin S, Roche MR, Duska LR, Pereira L, Kendall D, Penson RT
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer. J Clin Oncol. 2008 Dec 10; 26(35):5761-6.
Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer.
Management of women with newly diagnosed ovarian cancer. Semin Oncol. 2009 Apr; 36(2):91-105.
Management of women with newly diagnosed ovarian cancer.
Berkenblit A, Seiden MV, Matulonis UA, Penson RT, Krasner CN, Roche M, Mezzetti L, Atkinson T, Cannistra SA
A phase II trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancer. Gynecol Oncol. 2004 Dec; 95(3):624-31.
A phase II trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancer.
Roche MR, Rudd PJ, Krasner CN, Matulonis UA, Berlin ST, Lee H, Silver M, Tran CD, Seiden MV, Penson RT
Phase II trial of GM-CSF in women with asymptomatic recurrent müllerian tumors. Gynecol Oncol. 2010 Feb; 116(2):168-72.
Phase II trial of GM-CSF in women with asymptomatic recurrent müllerian tumors.
Monk BJ, Herzog TJ, Kaye SB, Krasner CN, Vermorken JB, Muggia FM, Pujade-Lauraine E, Lisyanskaya AS, Makhson AN, Rolski J, Gorbounova VA, Ghatage P, Bidzinski M, Shen K, Ngan HY, Vergote IB, Nam JH, Park YC, Lebedinsky CA, Poveda AM
Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer. J Clin Oncol. 2010 Jul 01; 28(19):3107-14.
Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer.
Monk BJ, Herzog TJ, Kaye SB, Krasner CN, Vermorken JB, Muggia FM, Pujade-Lauraine E, Park YC, Parekh TV, Poveda AM
European journal of cancer (Oxford, England : 1990)
Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: overall survival analysis. Eur J Cancer. 2012 Oct; 48(15):2361-8.
Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: overall survival analysis.
Matulonis UA, Campos S, Krasner CN, Duska LR, Penson RT, Falke R, Roche M, Smith LM, Lee H, Seiden MV
Three sequential chemotherapy doublets for the treatment of newly diagnosed advanced müllerian malignancies: the modified triple doublet regimen. Gynecol Oncol. 2006 Nov; 103(2):575-80.
Three sequential chemotherapy doublets for the treatment of newly diagnosed advanced müllerian malignancies: the modified triple doublet regimen.
Growdon WB, Lopez-Varela E, Littell R, Oliva E, Seiden M, Krasner C, Lee H, Fuller A
Extent of extracranial disease is a powerful predictor of survival in patients with brain metastases from gynecological cancer. Int J Gynecol Cancer. 2008 Mar-Apr; 18(2):262-8.
Extent of extracranial disease is a powerful predictor of survival in patients with brain metastases from gynecological cancer.
Krasner CN, Poveda A, Herzog TJ, Vermorken JB, Kaye SB, Nieto A, Claret PL, Park YC, Parekh T, Monk BJ
Patient-reported outcomes in relapsed ovarian cancer: results from a randomized Phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD alone. Gynecol Oncol. 2012 Oct; 127(1):161-7.
Patient-reported outcomes in relapsed ovarian cancer: results from a randomized Phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD alone.
del Campo JM, Sessa C, Krasner CN, Vermorken JB, Colombo N, Kaye S, Gore M, Zintl P, Gómez J, Parekh T, Park YC, McMeekin S
Medical oncology (Northwood, London, England)
Trabectedin as single agent in relapsed advanced ovarian cancer: results from a retrospective pooled analysis of three phase II trials. Med Oncol. 2013 Mar; 30(1):435.
Trabectedin as single agent in relapsed advanced ovarian cancer: results from a retrospective pooled analysis of three phase II trials.
Krasner CN, Castro C, Penson RT, Roche M, Matulonis UA, Morgan MA, Drescher C, Armstrong DK, Wolfe JK, Lee H, Supko JG, Seiden M, Birrer MJ, Dizon DS
Final report on serial phase II trials of all-intraperitoneal chemotherapy with or without bevacizumab for women with newly diagnosed, optimally cytoreduced carcinoma of Müllerian origin. Gynecol Oncol. 2019 05; 153(2):223-229.
Final report on serial phase II trials of all-intraperitoneal chemotherapy with or without bevacizumab for women with newly diagnosed, optimally cytoreduced carcinoma of Müllerian origin.
Alimena S, Fiascone S, Krasner C, King M, Horowitz N
A tumor board report of an 83-year-old woman with stage IB grade 3 endometrioid endometrial adenocarcinoma. Curr Probl Cancer. 2019 10; 43(5):443-449.
A tumor board report of an 83-year-old woman with stage IB grade 3 endometrioid endometrial adenocarcinoma.
Antineoplastic Combined Chemotherapy Protocols
Panagiotis Konstantinopoulos, M.D., Ph.D.
Associate Professor of Obstetrics, Gynecology and Reproductive Biology
George P. Canellos, MD, and Jean S. Canellos Professor of Medicine Professor of Medicine
Konstantinopoulos PA, Luo W, Liu JF, Gulhan DC, Krasner C, Ishizuka JJ, Gockley AA, Buss M, Growdon WB, Crowe H, Campos S, Lindeman NI, Hill S, Stover E, Schumer S, Wright AA, Curtis J, Quinn R, Whalen C, Gray KP, Penson RT, Cannistra SA, Fleming GF, Matulonis UA
Phase II Study of Avelumab in Patients With Mismatch Repair Deficient and Mismatch Repair Proficient Recurrent/Persistent Endometrial Cancer. J Clin Oncol. 2019 10 20; 37(30):2786-2794.
Phase II Study of Avelumab in Patients With Mismatch Repair Deficient and Mismatch Repair Proficient Recurrent/Persistent Endometrial Cancer.
Lee EK, Xiong N, Cheng SC, Barry WT, Penson RT, Konstantinopoulos PA, Hoffman MA, Horowitz N, Dizon DS, Stover EH, Wright AA, Campos SM, Krasner C, Morrissey S, Whalen C, Quinn R, Matulonis UA, Liu JF
Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: A phase 2 clinical trial. Gynecol Oncol. 2020 10; 159(1):72-78.
Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: A phase 2 clinical trial.
Duska LR, Krasner CN, O'Malley DM, Hays JL, Modesitt SC, Mathews CA, Moore KN, Thaker PH, Miller A, Purdy C, Zamboni WC, Lucas AT, Supko JG, Schilder RJ
A phase Ib/II and pharmacokinetic study of EP0057 (formerly CRLX101) in combination with weekly paclitaxel in patients with recurrent or persistent epithelial ovarian, fallopian tube, or primary peritoneal cancer. Gynecol Oncol. 2021 03; 160(3):688-695.
A phase Ib/II and pharmacokinetic study of EP0057 (formerly CRLX101) in combination with weekly paclitaxel in patients with recurrent or persistent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Schrier E, Xiong N, Thompson E, Poort H, Schumer S, Liu JF, Krasner C, Campos SM, Horowitz NS, Feltmate C, Konstantinopoulos PA, Dinardo MM, Tayob N, Matulonis UA, Patel M, Wright AA
Stepping into survivorship pilot study: Harnessing mobile health and principles of behavioral economics to increase physical activity in ovarian cancer survivors. Gynecol Oncol. 2021 05; 161(2):581-586.
Stepping into survivorship pilot study: Harnessing mobile health and principles of behavioral economics to increase physical activity in ovarian cancer survivors.
Liu JF, Xiong N, Campos SM, Wright AA, Krasner C, Schumer S, Horowitz N, Veneris J, Tayob N, Morrissey S, West G, Quinn R, Matulonis UA, Konstantinopoulos PA
Phase II Study of the WEE1 Inhibitor Adavosertib in Recurrent Uterine Serous Carcinoma. J Clin Oncol. 2021 05 10; 39(14):1531-1539.
Phase II Study of the WEE1 Inhibitor Adavosertib in Recurrent Uterine Serous Carcinoma.
Krasner CN, Campos SM, Young CL, Chadda KR, Lee H, Birrer MJ, Horowitz NS, Konstantinopoulos PA, D'Ascanio AM, Matulonis UA, Penson RT
Sequential Phase II clinical trials evaluating CRLX101 as monotherapy and in combination with bevacizumab in recurrent ovarian cancer. Gynecol Oncol. 2021 09; 162(3):661-666.
Sequential Phase II clinical trials evaluating CRLX101 as monotherapy and in combination with bevacizumab in recurrent ovarian cancer.
Campos SM, Berlin S, Krasner CN, Whalen C, Atkinson T, Meegan K, Pereira L, Tyburski K, Lou W, Lee H, Horowitz N, Penson RT
A phase I study of AZD2171 and Temsirolimus in patients with advanced gynecological malignancies. Cancer Chemother Pharmacol. 2022 03; 89(3):423-430.
A phase I study of AZD2171 and Temsirolimus in patients with advanced gynecological malignancies.
Konstantinopoulos PA, Gockley AA, Xiong N, Krasner C, Horowitz N, Campos S, Wright AA, Liu JF, Shea M, Yeku O, Castro C, Polak M, Lee EK, Sawyer H, Bowes B, Moroney J, Cheng SC, Tayob N, Bouberhan S, Spriggs D, Penson RT, Fleming GF, Nucci MR, Matulonis UA
Evaluation of Treatment With Talazoparib and Avelumab in Patients With Recurrent Mismatch Repair Proficient Endometrial Cancer. JAMA Oncol. 2022 09 01; 8(9):1317-1322.
Evaluation of Treatment With Talazoparib and Avelumab in Patients With Recurrent Mismatch Repair Proficient Endometrial Cancer.
Campos S, Matulonis U, Berlin S, Horowitz N, Liu J, Krasner C, Hang L, Zarwan C, Barry W, Colella T, Whalen C, Shoni M, Lundquist C, Birrer MJ, Penson R
A randomized phase II trial of bevacizumab vs. bevacizumab and erlotinib as first-line consolidation after carboplatin, paclitaxel, and bevacizumab in newly diagnosed patients with mullerian tumors. Int J Clin Oncol. 2022 Dec; 27(12):1881-1890.
A randomized phase II trial of bevacizumab vs. bevacizumab and erlotinib as first-line consolidation after carboplatin, paclitaxel, and bevacizumab in newly diagnosed patients with mullerian tumors.
Konstantinopoulos PA, Lee EK, Xiong N, Krasner C, Campos S, Kolin DL, Liu JF, Horowitz N, Wright AA, Bouberhan S, Penson RT, Yeku O, Bowes B, Needham H, Hayes M, Sawyer H, Polak M, Shea M, Cheng SC, Castro C, Matulonis UA
A Phase II, Two-Stage Study of Letrozole and Abemaciclib in Estrogen Receptor-Positive Recurrent Endometrial Cancer. J Clin Oncol. 2023 01 20; 41(3):599-608.
A Phase II, Two-Stage Study of Letrozole and Abemaciclib in Estrogen Receptor-Positive Recurrent Endometrial Cancer.
Penson RT, Ambrosio AJ, Whalen CA, Krasner CN, Konstantinopoulos PA, Bradley C, Matulonis UA, Birrer MJ
Phase II Trials of Iniparib (BSI-201) in Combination with Gemcitabine and Carboplatin in Patients with Recurrent Ovarian Cancer. Oncologist. 2023 03 17; 28(3):252-257.
Phase II Trials of Iniparib (BSI-201) in Combination with Gemcitabine and Carboplatin in Patients with Recurrent Ovarian Cancer.
Gupta S, Hanna PE, Ouyang T, Yamada KS, Sawtell R, Wang Q, Katz-Agranov N, Feghali L, Krasner CN, Bouberhan S, Castro CM, Sise ME
Journal of the National Cancer Institute
Kidney function in patients with ovarian cancer treated with poly (ADP-ribose) polymerase (PARP) inhibitors. J Natl Cancer Inst. 2023 07 06; 115(7):831-837.
Kidney function in patients with ovarian cancer treated with poly (ADP-ribose) polymerase (PARP) inhibitors.
Konstantinopoulos PA, Xiong N, Krasner C, Liu JF, Sawyer H, Polak M, Needham H, Geddes M, Koppermann L, Shea M, Castro C, Cheng SC, Matulonis UA, Lee EK
Combined aromatase, CDK4/6 and PI3K blockade using letrozole/abemaciclib/LY3023414 in endometrial cancer. Gynecol Oncol Rep. 2024 Apr; 52:101348.
Combined aromatase, CDK4/6 and PI3K blockade using letrozole/abemaciclib/LY3023414 in endometrial cancer.
Pozzar RA, Enzinger AC, Howard C, Tavormina A, Matulonis UA, Campos S, Liu JF, Horowitz N, Konstantinopoulos PA, Krasner C, Wall JA, Sciacca K, Meyer LA, Lindvall C, Wright AA
Feasibility and acceptability of a nurse-led telehealth intervention (BOLSTER) to support patients with peritoneal carcinomatosis and their caregivers: A pilot randomized clinical trial. Gynecol Oncol. 2024 Sep; 188:1-7.
Feasibility and acceptability of a nurse-led telehealth intervention (BOLSTER) to support patients with peritoneal carcinomatosis and their caregivers: A pilot randomized clinical trial.
Martin LP, Krasner C, Rutledge T, Ibañes ML, Fernández-García EM, Kahatt C, Gómez MS, McMeekin S
Phase II study of weekly PM00104 (ZALYPSIS(®)) in patients with pretreated advanced/metastatic endometrial or cervical cancer. Med Oncol. 2013; 30(3):627.
Phase II study of weekly PM00104 (ZALYPSIS(®)) in patients with pretreated advanced/metastatic endometrial or cervical cancer.
Rauh-Hain JA, Guseh SH, Esselen KM, Growdon WB, Schorge JO, Horowitz NS, Krasner CN, del Carmen MG, Birrer MJ, Dizon DS
Patterns of recurrence in patients treated with bevacizumab in the primary treatment of advanced epithelial ovarian cancer. Int J Gynecol Cancer. 2013 Sep; 23(7):1219-25.
Patterns of recurrence in patients treated with bevacizumab in the primary treatment of advanced epithelial ovarian cancer.
Konstantinopoulos PA, Cai M, Lee EK, Krasner C, Campos SM, Liu JF, Horowitz NS, Shea M, Parsons HA, Wright AA, Bouberhan S, Penson RT, Yeku O, Hayes M, Sawyer H, Polak M, Castro CM, Cheng SC, Weipert CM, Matulonis UA
Serial Circulating Tumor DNA Sequencing to Monitor Response and Define Acquired Resistance to Letrozole/Abemaciclib in Endometrial Cancer. JCO Precis Oncol. 2025 Apr; 9:e2400882.
Serial Circulating Tumor DNA Sequencing to Monitor Response and Define Acquired Resistance to Letrozole/Abemaciclib in Endometrial Cancer.
Lee EK, Xiong N, Krasner C, Polak M, Campos S, Wright AA, Liu JF, Shea M, Yeku O, Castro C, Porter R, Stover EH, Koppermann L, Smith J, Sawyer H, Hayes M, Zhou N, Cheng SC, Bouberhan S, Pfaff KL, Rodig SJ, Jones S, Penson RT, Moroney J, Fleming GF, Matulonis UA, Konstantinopoulos PA
Phase 2, two-stage study of avelumab and axitinib in patients with mismatch repair proficient recurrent or persistent endometrial cancer. Gynecol Oncol. 2025 Jul; 198:1-8.
Phase 2, two-stage study of avelumab and axitinib in patients with mismatch repair proficient recurrent or persistent endometrial cancer.
George S, Feng Y, Manola J, Nucci MR, Butrynski JE, Morgan JA, Ramaiya N, Quek R, Penson RT, Wagner AJ, Harmon D, Demetri GD, Krasner C
Phase 2 trial of aromatase inhibition with letrozole in patients with uterine leiomyosarcomas expressing estrogen and/or progesterone receptors. Cancer. 2014 Mar 01; 120(5):738-43.
Phase 2 trial of aromatase inhibition with letrozole in patients with uterine leiomyosarcomas expressing estrogen and/or progesterone receptors.
Cham S, Xiong N, Tayob N, Krasner C, Wright AA, Lee EK, Sawyer H, Mathews C, Konstantinopoulos PA, Matulonis UA, Liu JF
Phase 2 study of Wee1 inhibitor adavosertib in recurrent uterine carcinosarcoma. Gynecol Oncol Rep. 2025 Aug; 60:101796.
Phase 2 study of Wee1 inhibitor adavosertib in recurrent uterine carcinosarcoma.
Konstantinopoulos PA, Zhou N, Penson RT, Le TV, Campos S, Krasner C, Wright AA, Porter R, Horowitz N, Bouberhan S, Liu JF, Hindenach S, Sawyer H, Koppermann L, Hayes M, Polak M, Shea M, Widick P, Cheng SC, Castro C, Beumer JH, Matulonis UA, Lee EK
Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial. Nat Commun. 2025 Dec 03; 17(1):395.
Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Moraxella catarrhalis bacteremia as a cause of erythema nodosum. Clin Infect Dis. 1996 Sep; 23(3):650-1.
Moraxella catarrhalis bacteremia as a cause of erythema nodosum.
Berek JS, Edwards RP, Parker LP, DeMars LR, Herzog TJ, Lentz SS, Morris RT, Akerley WL, Holloway RW, Method MW, Plaxe SC, Walker JL, Friccius-Quecke H, Krasner CN
Catumaxomab for the treatment of malignant ascites in patients with chemotherapy-refractory ovarian cancer: a phase II study. Int J Gynecol Cancer. 2014 Nov; 24(9):1583-9.
Catumaxomab for the treatment of malignant ascites in patients with chemotherapy-refractory ovarian cancer: a phase II study.
Liu SK, Rassai H, Krasner C, Braun J, Matolo NM
Surgical laparoscopy, endoscopy & percutaneous techniques
Urinary catheter in laparoscopic cholecystectomy: is it necessary? Surg Laparosc Endosc Percutan Tech. 1999 Jun; 9(3):184-6.
Urinary catheter in laparoscopic cholecystectomy: is it necessary?
Pham E, Birrer MJ, Eliasof S, Garmey EG, Lazarus D, Lee CR, Man S, Matulonis UA, Peters CG, Xu P, Krasner C, Kerbel RS
Clinical cancer research : an official journal of the American Association for Cancer Research
Translational impact of nanoparticle-drug conjugate CRLX101 with or without bevacizumab in advanced ovarian cancer. Clin Cancer Res. 2015 Feb 15; 21(4):808-18.
Translational impact of nanoparticle-drug conjugate CRLX101 with or without bevacizumab in advanced ovarian cancer.
Matulonis U, Berlin S, Lee H, Whalen C, Obermayer E, Penson R, Liu J, Campos S, Krasner C, Horowitz N
Phase I study of combination of vorinostat, carboplatin, and gemcitabine in women with recurrent, platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer. Cancer Chemother Pharmacol. 2015 Aug; 76(2):417-23.
Phase I study of combination of vorinostat, carboplatin, and gemcitabine in women with recurrent, platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer.
Penson RT, Sales E, Sullivan L, Borger DR, Krasner CN, Goodman AK, del Carmen MG, Growdon WB, Schorge JO, Boruta DM, Castro CM, Dizon DS, Birrer MJ
A SNaPshot of potentially personalized care: Molecular diagnostics in gynecologic cancer. Gynecol Oncol. 2016 Apr; 141(1):108-12.
A SNaPshot of potentially personalized care: Molecular diagnostics in gynecologic cancer.
Del Carmen MG, Supko JG, Horick NK, Rauh-Hain JA, Clark RM, Campos SM, Krasner CN, Atkinson T, Birrer MJ
Phase 1 and 2 study of carboplatin and pralatrexate in patients with recurrent, platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer. Cancer. 2016 Nov 15; 122(21):3297-3306.
Phase 1 and 2 study of carboplatin and pralatrexate in patients with recurrent, platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer.
Krasner CN, Seiden MV, Fuller AF, Roche M, Verrill CL, D'Amato F, Tretyakov O, Tyburski K, Matulonis UA, Supko JG
Pharmacokinetic analysis of an all intraperitoneal carboplatin and paclitaxel regimen in ovarian cancer patients demonstrates favorable systemic bioavailability of both agents. J Clin Oncol. 2006 Jun 20; 24(18_suppl):5008.
Pharmacokinetic analysis of an all intraperitoneal carboplatin and paclitaxel regimen in ovarian cancer patients demonstrates favorable systemic bioavailability of both agents.
Roche M, Matulonis U, Krasner C, Penson R, Horowitz N, Berkenblit A, Findley M, Lee J, Horick N, Seiden MV
Phase II trial of GM-CSF in women with asymptomatic müllerian cancer. J Clin Oncol. 2006 Jun 20; 24(18_suppl):5081.
Phase II trial of GM-CSF in women with asymptomatic müllerian cancer.
Penson RT, Cannistra SA, Seiden MV, Krasner CN, Matulonis UA, Horowitz NS, Berlin S, Dizon DS, Lee H, Campos SM
Phase II study of carboplatin, paclitaxel and bevacizumab as first line chemotherapy and consolidation for advanced müllerian tumors. J Clin Oncol. 2006 Jun 20; 24(18_suppl):5020.
Phase II study of carboplatin, paclitaxel and bevacizumab as first line chemotherapy and consolidation for advanced müllerian tumors.
Miller DS, Blessing JA, Krasner CN, Drake RD, Higgins R, McMeekin DS, Puneky LV
A phase II evaluation of pemetrexed (ALIMTA, LY231514, IND#40061) in the treatment of recurrent or persistent endometrial carcinoma: A phase II study of the Gynecologic Oncology Group. J Clin Oncol. 2009 May 20; 27(15_suppl):e16507.
A phase II evaluation of pemetrexed (ALIMTA, LY231514, IND#40061) in the treatment of recurrent or persistent endometrial carcinoma: A phase II study of the Gynecologic Oncology Group.
Campos SM, Parker L, Chen W, Bunnell CA, Atkinson T, Lee J, Matulonis UA, Harris LN, Krasner CN
Phase I trial of liposomal doxorubicin and ZD 1839 in patients with refractory gynecological malignancies or metastatic breast cancer. J Clin Oncol. 2006 Jun 20; 24(18_suppl):5085.
Phase I trial of liposomal doxorubicin and ZD 1839 in patients with refractory gynecological malignancies or metastatic breast cancer.
Krasner CN, Poveda A, Herzog T, Vermorken J, Monk B, Zintl P, Li J, Su Y, Dhawan R, Kaye S
Health-related quality of life/patient-reported outcomes in relapsed ovarian cancer: Results from a randomized phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD alone. J Clin Oncol. 2009 May 20; 27(15_suppl):5526.
Health-related quality of life/patient-reported outcomes in relapsed ovarian cancer: Results from a randomized phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD alone.
Krasner CN, McMeekin S, Chan S, Braly P, Kaye S, Provencher D, Klecz J, Michiels B, Van de Velde H, Gore M
A phase II study of weekly trabectedin (ET-743) in second/third line ovarian carcinoma. J Clin Oncol. 2004 Jul 15; 22(14_suppl):5045.
A phase II study of weekly trabectedin (ET-743) in second/third line ovarian carcinoma.
Monk BJ, Herzog TJ, Kaye SB, Krasner CN, Vermorken JB, Muggia F, Pujade-Lourraine E, Zintl P, Parekh TV, Poveda A
Final survival results of the randomized phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer. J Clin Oncol. 2011 May 20; 29(15_suppl):5046.
Final survival results of the randomized phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer.
Penson RT, Seiden MV, Campos SM, Krasner CN, Fuller AF, Goodman A, Roche M, Willman A, Muzikansky A, Matulonis UA
A phase II study of fixed dose-rate gemcitabine in patients with relapsed Müllerian tumors. J Clin Oncol. 2004 Jul 15; 22(14_suppl):5151.
A phase II study of fixed dose-rate gemcitabine in patients with relapsed Müllerian tumors.
Matulonis U, Krasner C, Atkinson T, Penson R
Long-acting octreotide for the treatment of symptoms of bowel obstruction and intermittent obstruction in advanced ovarian cancer. J Clin Oncol. 2004 Jul 15; 22(14_suppl):5148.
Long-acting octreotide for the treatment of symptoms of bowel obstruction and intermittent obstruction in advanced ovarian cancer.
Penson RT, Whalen C, Lasonde B, Krasner CN, Konstantinopoulos P, Stallings TE, Bradley CR, Birrer MJ, Matulonis U
A phase II trial of iniparib (BSI-201) in combination with gemcitabine/carboplatin (GC) in patients with platinum-sensitive recurrent ovarian cancer. J Clin Oncol. 2011 May 20; 29(15_suppl):5004.
A phase II trial of iniparib (BSI-201) in combination with gemcitabine/carboplatin (GC) in patients with platinum-sensitive recurrent ovarian cancer.
Berek JS, Edwards RP, Parker L, DeMars LR, Herzog TJ, Lentz SS, Morris R, Akerley WL, Holloway RW, Method M, Plaxe SC, Walker JL, Schindler T, Schulze E, Krasner CN
Catumaxomab treatment of malignant ascites in patients with chemotherapy-refractory ovarian cancer: A phase II study. J Clin Oncol. 2011 May 20; 29(15_suppl):5048.
Catumaxomab treatment of malignant ascites in patients with chemotherapy-refractory ovarian cancer: A phase II study.
Lax T, Dizon DS, Birrer M, Long A, Del Carmen M, Goodman A, Krasner C, Penson RT, Growdon W, Camargo CA, Banerji A
The journal of allergy and clinical immunology. In practice
Extended carboplatin infusion does not reduce frequency of hypersensitivity reaction at initiation of retreatment in patients with recurrent platinum-sensitive ovarian cancer. J Allergy Clin Immunol Pract. 2017 Jan - Feb; 5(1):177-178.
Extended carboplatin infusion does not reduce frequency of hypersensitivity reaction at initiation of retreatment in patients with recurrent platinum-sensitive ovarian cancer.
Miller DS, Blessing JA, Krasner CN, Mannel RJ
A phase II evaluation of pemetrexed (LY231514, IND #40061) in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: A study of the gynecologic oncology group. J Clin Oncol. 2008 May 20; 26(15_suppl):5524.
A phase II evaluation of pemetrexed (LY231514, IND #40061) in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: A study of the gynecologic oncology group.
Penson RT, Kornblith AB, Lee J, Roche M, Atkinson T, Gibson CD, Horowitz NS, Krag KJ, Krasner CN, Matulonis UA
Phase II study of carboplatin and paclitaxel in elderly women with newly diagnosed ovarian, peritoneal, or fallopian tube cancer. J Clin Oncol. 2008 May 20; 26(15_suppl):5590.
Phase II study of carboplatin and paclitaxel in elderly women with newly diagnosed ovarian, peritoneal, or fallopian tube cancer.
Matulonis UA, Berlin ST, Krasner CN, Tyburski K, Lee J, Roche M, Ivy SP, Lenahan C, King M, Penson RT
Cediranib (AZD2171) is an active agent in recurrent epithelial ovarian cancer. J Clin Oncol. 2008 May 20; 26(15_suppl):5501.
Cediranib (AZD2171) is an active agent in recurrent epithelial ovarian cancer.
Matulonis UA, Campos S, Krasner C, Duska L, Penson RP, Falke R, Roche M, Smith LM, Lee H, Seiden MV
A phase II trial of modified triple doublets for the treatment of advanced Müllerian malignancies. J Clin Oncol. 2005 Jun; 23(16_suppl):5010.
A phase II trial of modified triple doublets for the treatment of advanced Müllerian malignancies.
Penson RT, Krasner CN, Seiden MV, Atkinson T, Kornblith A, Campos S, Klein A, Matulonis U
Long-acting octreotide for the treatment of symptoms of bowel obstruction in advanced ovarian cancer. J Clin Oncol. 2005 Jun; 23(16_suppl):5159.
Long-acting octreotide for the treatment of symptoms of bowel obstruction in advanced ovarian cancer.
Horowitz NS, Penson RT, Campos SM, Lee J, Kendall DL, Krasner CN, Berlin ST, Roche M, Duska LR, Matulonis UA
Combination carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer. J Clin Oncol. 2008 May 20; 26(15_suppl):5523.
Combination carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer.
McMeekin DS, Krasner C, Chan S, Braly P, Kaye S, Provencher D, Trifan OC, Michiels B, Gore M
Final results of a phase II study of weekly trabectedin in second/third line ovarian carcinoma. J Clin Oncol. 2005 Jun; 23(16_suppl):5011.
Final results of a phase II study of weekly trabectedin in second/third line ovarian carcinoma.
Krasner CN, Debernardo RL, Findley M, Penson R, Matulonis U, Atkinson T, Roche M, Seiden MV
Phase II trial of anastrazole in combination with gefitinib in women with asymptomatic mullerian cancer. J Clin Oncol. 2005 Jun; 23(16_suppl):5063.
Phase II trial of anastrazole in combination with gefitinib in women with asymptomatic mullerian cancer.
Krasner CN, Seiden MV, Penson RT, Roche M, Kendall DL, Young J, Matulonis UA, Pereira L, Berlin ST
NOV-002 plus carboplatin in platinum-resistant ovarian cancer. J Clin Oncol. 2008 May 20; 26(15_suppl):5593.
NOV-002 plus carboplatin in platinum-resistant ovarian cancer.
Kornblith AB, Powell M, Regan MM, Bennett S, Krasner C, Moy B, Younger J, Goodman A, Berkowitz R, Winer E
Erratum: Long-term psychosocial adjustment of older vs younger survivors of breast and endometrial cancer. Psychooncology. 2007 May 24; 16(10).
Erratum: Long-term psychosocial adjustment of older vs younger survivors of breast and endometrial cancer.
Penson RT, Dizon DS, Cannistra SA, Roche MR, Krasner CN, Berlin ST, Horowitz NS, Disilvestro PA, Matulonis UA, Lee H, King MA, Campos SM
Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors. J Clin Oncol. 2010 Jan 01; 28(1):154-9.
Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors.
Penson RT, Seiden MV, Goodman A, Fuller AF, Berkowitz RS, Matulonis UA, Krasner C, Lee H, Atkinson T, Campos SM
Phase I trial of escalating doses of topotecan in combination with a fixed dose of pegylated liposomal doxorubicin in women with müllerian malignancies. Gynecol Oncol. 2004 Jun; 93(3):702-7.
Phase I trial of escalating doses of topotecan in combination with a fixed dose of pegylated liposomal doxorubicin in women with müllerian malignancies.
Kanwar VS, Heath J, Krasner CN, Pearce JM
Advanced small cell carcinoma of the ovary in a seventeen-year-old female, successfully treated with surgery and multi-agent chemotherapy. Pediatr Blood Cancer. 2008 May; 50(5):1060-2.
Advanced small cell carcinoma of the ovary in a seventeen-year-old female, successfully treated with surgery and multi-agent chemotherapy.
Schwaber MJ, Krasner CN, Gold HS, Venkataraman L, Avigan DE, Karchmer AW, Uhl L
Detection of Staphylococcus aureus in peripheral blood stem cell cultures after sterilization of standard blood cultures. J Clin Apher. 2003; 18(1):37-9.
Detection of Staphylococcus aureus in peripheral blood stem cell cultures after sterilization of standard blood cultures.
Olawaiye A, Lee LM, Krasner C, Horowitz N
Treatment of squamous cell vulvar cancer with the anti-EGFR tyrosine kinase inhibitor Tarceva. Gynecol Oncol. 2007 Sep; 106(3):628-30.
Treatment of squamous cell vulvar cancer with the anti-EGFR tyrosine kinase inhibitor Tarceva.
Long-term psychosocial adjustment of older vs younger survivors of breast and endometrial cancer. Psychooncology. 2007 Oct; 16(10):895-903.
Long-term psychosocial adjustment of older vs younger survivors of breast and endometrial cancer.
Krasner CN, Roche M, Horowitz NS, Supko JG, Lee SI, Oliva E
Case records of the Massachusetts General Hospital. Case 11-2006. A 54-year-old woman with a mass in the pelvis. N Engl J Med. 2006 Apr 13; 354(15):1615-25.
Case records of the Massachusetts General Hospital. Case 11-2006. A 54-year-old woman with a mass in the pelvis.
The Journal of steroid biochemistry and molecular biology
Aromatase inhibitors in gynecologic cancers. J Steroid Biochem Mol Biol. 2007 Aug-Sep; 106(1-5):76-80.
Aromatase inhibitors in gynecologic cancers.
Horowitz NS, Penson RT, Duda DG, di Tomaso E, Boucher Y, Ancukiewicz M, Cohen KS, Berlin S, Krasner CN, Moses MA, Jain RK
Clinical ovarian cancer and other gynecologic malignancies
Safety, Efficacy, and Biomarker Exploration in a Phase II Study of Bevacizumab, Oxaliplatin, and Gemcitabine in Recurrent Müllerian Carcinoma. Clin Ovarian Cancer Other Gynecol Malig. 2011 Jun; 4(1):26-33.
Safety, Efficacy, and Biomarker Exploration in a Phase II Study of Bevacizumab, Oxaliplatin, and Gemcitabine in Recurrent Müllerian Carcinoma.
Vaidya AP, Littell R, Krasner C, Duska LR
Treatment of uterine papillary serous carcinoma with platinum-based chemotherapy and paclitaxel. Int J Gynecol Cancer. 2006 Jan-Feb; 16 Suppl 1:267-72.
Treatment of uterine papillary serous carcinoma with platinum-based chemotherapy and paclitaxel.
Matulonis UA, Campos S, Duska L, Krasner CN, Atkinson T, Penson RT, Seiden MV, Verrill C, Fuller AF, Goodman A
Phase I/II dose finding study of combination cisplatin and gemcitabine in patients with recurrent cervix cancer. Gynecol Oncol. 2006 Oct; 103(1):160-4.
Phase I/II dose finding study of combination cisplatin and gemcitabine in patients with recurrent cervix cancer.
Miller DS, Blessing JA, Krasner CN, Mannel RS, Hanjani P, Pearl ML, Waggoner SE, Boardman CH
Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group. J Clin Oncol. 2009 Jun 01; 27(16):2686-91.
Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group.
Krasner CN, McMeekin DS, Chan S, Braly PS, Renshaw FG, Kaye S, Provencher DM, Campos S, Gore ME
A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens. Br J Cancer. 2007 Dec 17; 97(12):1618-24.
A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens.
Matulonis UA, Krag KJ, Krasner CN, Atkinson T, Horowitz NS, Lee H, Penson RT
Phase II prospective study of paclitaxel and carboplatin in older patients with newly diagnosed Müllerian tumors. Gynecol Oncol. 2009 Feb; 112(2):394-9.
Phase II prospective study of paclitaxel and carboplatin in older patients with newly diagnosed Müllerian tumors.
Matulonis UA, Berlin S, Ivy P, Tyburski K, Krasner C, Zarwan C, Berkenblit A, Campos S, Horowitz N, Cannistra SA, Lee H, Lee J, Roche M, Hill M, Whalen C, Sullivan L, Tran C, Humphreys BD, Penson RT
Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J Clin Oncol. 2009 Nov 20; 27(33):5601-6.
Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer.
Miller DS, Blessing JA, Drake RD, Higgins R, McMeekin DS, Puneky LV, Krasner CN
A phase II evaluation of pemetrexed (Alimta, LY231514, IND #40061) in the treatment of recurrent or persistent endometrial carcinoma: a phase II study of the Gynecologic Oncology. Gynecol Oncol. 2009 Dec; 115(3):443-6.
A phase II evaluation of pemetrexed (Alimta, LY231514, IND #40061) in the treatment of recurrent or persistent endometrial carcinoma: a phase II study of the Gynecologic Oncology.
Horowitz NS, Olawaiye AB, Borger DR, Growdon WB, Krasner CN, Matulonis UA, Liu JF, Lee J, Brard L, Dizon DS
Phase II trial of erlotinib in women with squamous cell carcinoma of the vulva. Gynecol Oncol. 2012 Oct; 127(1):141-6.
Phase II trial of erlotinib in women with squamous cell carcinoma of the vulva.
Matulonis UA, Seiden MV, Roche M, Krasner C, Fuller AF, Atkinson T, Kornblith A, Penson R
Long-acting octreotide for the treatment and symptomatic relief of bowel obstruction in advanced ovarian cancer. J Pain Symptom Manage. 2005 Dec; 30(6):563-9.
Long-acting octreotide for the treatment and symptomatic relief of bowel obstruction in advanced ovarian cancer.